Market research
2CX.F ChemoCentryx, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 52
- Dividend yield
- 0.0%
- Beta
- 1.23
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US16383L1061
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 52
- Dividend yield
- 0.0%
- Beta
- 1.23
About
About ChemoCentryx, Inc
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2CX.F discussion.
5 years, 5 months ago
ChemoCentryx, Inc is currently in a long term downtrend where the price is trading 68.3% below its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 51.4.
ChemoCentryx, Inc's total revenue sank by 57.2% to $4M since the same quarter in the previous year.
Its net income has dropped by 92.4% to $-30M since the same quarter in the previous year.
Finally, its free cash flow fell by 38.6% to $-28M since the same quarter in the previous year.
Based on the above factors, ChemoCentryx, Inc gets an overall score of 1/5.